$1.11 Billion is the total value of GREAT POINT PARTNERS LLC's 34 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $127,618,000 | +24.8% | 3,876,600 | +4.1% | 11.48% | +40.5% |
| SAGE | Sell | SAGE THERAPEUTICS INC | $120,204,000 | +37.5% | 1,966,688 | -6.5% | 10.81% | +54.7% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $79,264,000 | -9.4% | 1,921,563 | +6.5% | 7.13% | +2.0% |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $74,558,000 | -9.1% | 996,898 | -23.5% | 6.71% | +2.3% |
| ZYME | Sell | ZYMEWORKS INC | $73,033,000 | -21.4% | 1,567,900 | -39.1% | 6.57% | -11.5% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $64,718,000 | -13.7% | 640,773 | +3.4% | 5.82% | -2.9% |
| CNST | Sell | CONSTELLATION PHARMCETICLS I | $57,983,000 | -44.6% | 2,861,924 | -17.8% | 5.22% | -37.6% |
| CYTK | Buy | CYTOKINETICS INC | $55,197,000 | +54.0% | 2,549,525 | +67.7% | 4.96% | +73.3% |
| GWPH | Buy | GW PHARMACEUTICALS PLCads | $50,645,000 | -8.3% | 520,232 | +15.6% | 4.56% | +3.2% |
| TGTX | Sell | TG THERAPEUTICS INC | $42,816,000 | -33.8% | 1,600,000 | -51.8% | 3.85% | -25.5% |
| MGNX | Buy | MACROGENICS INC | $38,042,000 | -9.2% | 1,510,215 | +0.7% | 3.42% | +2.2% |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $36,609,000 | – | 2,485,327 | +100.0% | 3.29% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $36,154,000 | +5.6% | 655,676 | +20.9% | 3.25% | +18.9% |
| BHVN | Sell | BIOHAVEN PHARMACTL HLDG CO L | $28,279,000 | -54.0% | 435,000 | -48.3% | 2.54% | -48.2% |
| VCEL | Sell | VERICEL CORP | $27,439,000 | +23.3% | 1,480,787 | -8.0% | 2.47% | +38.7% |
| GKOS | Sell | GLAUKOS CORP | $22,091,000 | +15.0% | 446,097 | -10.8% | 1.99% | +29.4% |
| GERN | Sell | GERON CORP | $16,853,000 | -49.8% | 9,685,528 | -37.1% | 1.52% | -43.5% |
| PRTA | Sell | PROTHENA CORP PLC | $15,469,000 | -29.0% | 1,548,479 | -25.7% | 1.39% | -20.1% |
| SGMO | Buy | SANGAMO THERAPEUTICS INC | $15,023,000 | +6.1% | 1,589,724 | +0.6% | 1.35% | +19.3% |
| CCXI | New | CHEMOCENTRYX INC | $13,877,000 | – | 253,230 | +100.0% | 1.25% | – |
| TBIO | New | TRANSLATE BIO INC | $12,839,000 | – | 943,339 | +100.0% | 1.16% | – |
| ALLO | New | ALLOGENE THERAPEUTICS INC | $12,400,000 | – | 328,817 | +100.0% | 1.12% | – |
| XENT | New | INTERSECT ENT INC | $12,199,000 | – | 747,926 | +100.0% | 1.10% | – |
| IVA | New | INVENTIVA SAads | $11,813,000 | – | 999,422 | +100.0% | 1.06% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $11,120,000 | +1052.3% | 1,102,073 | +1091.4% | 1.00% | +1198.7% |
| CALA | Buy | CALITHERA BIOSCIENCES INC | $10,069,000 | -15.7% | 2,918,581 | +29.0% | 0.91% | -5.1% |
| KDMN | Buy | KADMON HLDGS INC | $9,800,000 | +183.3% | 2,500,000 | +270.0% | 0.88% | +219.6% |
| VRAY | Sell | VIEWRAY INC | $9,295,000 | +49.6% | 2,655,763 | -4.3% | 0.84% | +68.2% |
| LNTH | New | LANTHEUS HLDGS INC | $7,535,000 | – | 594,750 | +100.0% | 0.68% | – |
| LQDA | Sell | LIQUIDIA TECHNOLOGIES INC | $5,853,000 | -45.6% | 1,189,607 | -6.9% | 0.53% | -38.7% |
| CYTK | New | CYTOKINETICS INCput | $5,477,000 | – | 253,000 | +100.0% | 0.49% | – |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $3,971,000 | -81.1% | 3,892,921 | -46.0% | 0.36% | -78.8% |
| MLND | Sell | MILLENDO THERAPEUTICS INC | $1,920,000 | -25.3% | 1,177,900 | -19.4% | 0.17% | -16.0% |
| OYST | Sell | OYSTER PT PHARMA INC | $1,480,000 | -76.1% | 70,121 | -67.3% | 0.13% | -73.2% |
| NLTX | Exit | NEOLEUKIN THERAPEUTICS INC | $0 | – | -14,065 | -100.0% | -0.02% | – |
| XLRN | Exit | ACCELERON PHARMA INC | $0 | – | -58,056 | -100.0% | -0.44% | – |
| DNLI | Exit | DENALI THERAPEUTICS INC | $0 | – | -280,000 | -100.0% | -0.54% | – |
| ARVN | Exit | ARVINAS INCcall | $0 | – | -203,500 | -100.0% | -0.55% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -1,448,604 | -100.0% | -0.96% | – |
| AXNX | Exit | AXONICS MODULATION TECHNOLOG | $0 | – | -459,503 | -100.0% | -1.29% | – |
| PTCT | Exit | PTC THERAPEUTICS INC | $0 | – | -330,000 | -100.0% | -1.34% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -1,345,397 | -100.0% | -1.48% | – |
| NXTC | Exit | NEXTCURE INC | $0 | – | -999,666 | -100.0% | -1.71% | – |
| AKBA | Exit | AKEBIA THERAPEUTICS INC | $0 | – | -3,510,073 | -100.0% | -3.81% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.